Overview

Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Study to Evaluate Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.